Skip to content
Home / What the 2012 SAMHSA Guidelines on EtG/EtS Means for Drug Courts

What the 2012 SAMHSA Guidelines on EtG/EtS Means for Drug Courts

This webinar is designed to review the recently revised Advisory from SAMHSA entitled: "The Role of Biomarkers in the Treatment of Alcohol Disorders, 2012 Revision.  Ethyl glucuronide (EtG) and ethyl sulfate (EtS) have become critical tests in the abstinence monitoring of alcohol in drug court settings.  The original SAMHSA Advisory (September, 2006) caused a significant chilling effect on the utility of EtG/EtS testing and raised questions regarding the appropriate use of this valuable monitoring tool in a forensic context.  Drug Courts have been anxiously awaiting these revisions.  The following issues related to the revised advisory will be discussed during this webinar:

  • Review of both indirect and direct alcohol biomarkers and their use
  • Discussion of what alcohol biomarkers are most appropriate for use in therapeutic/treatment courts settings
  • Evaluation of EtG/EtS cutoff concentrations appropriate for therapeutic/ treatment courts case adjudication
  • Review of the importance of a client contract when utilizing EtG/EtS testing for alcohol abstinence monitoring
  • Comparison of EtG/EtS testing methods
  • Best practices for therapeutic/treatment courts using or planning to use EtG/EtS testing

Presented by Paul Carey

View Webinar

Leave a Comment